shutterstock_1436567156_jonathan_weiss
Jonathan Weiss / Shutterstock.com
5 August 2021GenericsAlex Baldwin

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
29 August 2017   AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
1 August 2017   Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.

More on this story

Asia
29 August 2017   AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
1 August 2017   Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.

More on this story

Asia
29 August 2017   AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
1 August 2017   Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.